Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 326–350 of 835 studies in Prevention trials (page 14 of 34) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Prevention trials” covers

Prevention trials — Trials that test whether a specific diet, lifestyle change or supplement actually slows cognitive decline.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Despite the growing interest in cognitive training programs as a potential non-pharmacological approach to slowing cognitive decline in mild cognitive impairment (MCI), there has been little research on the differential effectiveness of training among subtypes of MCI (i.e., amnestic, single non-amnestic, and multi-domain). 2 key findings →

Design: longitudinal study Evidence: moderate

Our findings suggest a potential protective role of green spaces on mental health (depression and anxiety) in adults, but further studies, especially longitudinal studies, are needed to provide further evidence of these benefits and of the mediation role of exposures like air pollution and noise. 5 key findings →

Design: longitudinal study Evidence: moderate

Metals, Nanoparticles, Particulate Matter, and Cognitive Decline

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Frontiers in neurology 2022-01-21

Exposure to metals is ubiquitous and emission sources include gasoline, diesel, smoke from wildfires, contaminated soil, water and food, medical implants, waste recycling facilities, subway exposures, and occupational environments. 1 key finding →

Design: longitudinal study Evidence: moderate

Diffusion MRI of Gray Matter Microstructural Profiles in Healthy Aging

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neuroscience and biobehavioral reviews 2026-08-06

Diffusion-weighted imaging (DWI) is a non-invasive magnetic resonance imaging (MRI) acquisition technique that can provide detailed information about brain microstructure. 1 key finding →

Design: longitudinal study Evidence: moderate

Neurodegenerative disorders such as Alzheimer's disease (AD), the most common form of dementia, represent a growing global health crisis, yet current treatment strategies remain primarily palliative. 2 key findings →

Design: longitudinal study Evidence: moderate

After the intervention, the CG showed significantly lower scores compared to all experimental groups. 4 key findings →

Design: randomized controlled trial Participants: 92 Evidence: high

Combining aerobic exercise with cognitive training improves clinical outcomes in older adults with MCI and may influence stress-related neurobiological pathways. 5 key findings →

Design: randomized controlled trial Participants: 28 Evidence: high

Among the five personality domains, only extraversion was significantly associated with reduced odds of cognitive decline within the intervention group over 24 weeks (fully adjusted model: OR = 0.35; 95% CI: 0.15-0.82). 2 key findings →

Design: randomized controlled trial Participants: 136 Evidence: high

Mild cognitive impairment (MCI) increases the risk of dementia. 3 key findings →

Design: randomized controlled trial Participants: 84 Evidence: high

= 0.279). No adverse events were reported. 2 key findings →

Design: randomized controlled trial Evidence: high

LIGHT will provide insight into the implementation and (cost-)effectiveness of a lifestyle intervention for indicated prevention in a memory clinic setting. 2 key findings →

Design: randomized controlled trial Evidence: high

There were 656 deaths, 1585 incidents of CVD and 165 dementia diagnoses during 17.2 years of follow-up. 5 key findings →

Design: longitudinal study Participants: 9,584 Evidence: moderate

This disease is associated with numerous restrictions for those affected but also for caregivers and society. 2 key findings →

Design: randomized controlled trial Participants: 200 Evidence: high

We here review evidence gathered for nearly a decade on non-invasive brain stimulation (NIBS), a less known therapeutic strategy aiming to limit cognitive decline associated with neurodegenerative conditions. 1 key finding →

Participants: 70 Evidence: high

Stronger adherence to the Mediterranean diet may reduce the rate of cognitive decline among black, but not white older adults. 4 key findings →

Design: cohort study Evidence: moderate

Age and higher baseline BMI, independent of gender, and other confounding factors, are risk factors for cognitive decline. 4 key findings →

Design: longitudinal study Evidence: moderate

Following a Mediterranean diet high in plant-based foods and fish, low in meat and dairy foods, and with moderate alcohol intake has been shown to promote healthy aging. 1 key finding →

Participants: 832 Evidence: low

A total of 887 (69.5%) participants reported incident difficulty in at least one IADL task category. 5 key findings →

Participants: 1,277 Evidence: low

Alzheimer's disease (AD) affects approximately 35 million people worldwide. 2 key findings →

Design: cohort study Evidence: moderate

Effect of aerobic exercise on white matter microstructure in the aging brain

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Behavioural brain research 2019-07-04

Aging is associated with decline in white matter (WM) microstructure, decreased cognitive functioning, and increased risk of Alzheimer's disease and related dementias. 5 key findings →

Design: longitudinal study Evidence: moderate

Both groups exhibited significant, transient microbiome remodeling at Year 1 (the period of most active weight loss). 5 key findings →

Design: randomized controlled trial Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed